REGULATORY

MHLW Panel OKs Pfizer’s Vyndaqel for Sakigake-Designated Use

February 22, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Pfizer’s Vyndaqel (tafamidis) gained the nod from a key health ministry committee for a sakigake-designated indication along with a batch of new drugs on February 21. These products are expected to earn the official seal of approval as early as…

To read the full story

MHLW Approves Vyvanse, Biktarvy, Trelegy, Vyndaqel, Dupixent Asthma Use and More
March 27, 2019
Vyvanse Clears MHLW Panel after a Hold; Approval Expected in March
February 22, 2019

REGULATORY

PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…